NR3C2 and hypereosinophilic syndrome: Fourth, imaging data, prescribing data (renin-angiotensin-aldosterone system blockade, beta-blocker, mineralocorticoid receptor antagonist), non-pharmacological therapy use, laboratory data, requirement for social care, and quality of life data are not available in HES, which limited our ability to phenotype patient cohorts at baseline, determine completeness of revascularization, or to validate outcomes.